“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” said Doug Langa, executive vice president, North America operations and president of Novo Nordisk.
Plaintiff’s False Testimony Over ‘Almost Verbatim Text’ Lead to Dismissal, Judge Rules
“The court has no reason to believe that, if given
